TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10233334

Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) 5% in ethanol applied in a chamber for 4 hours on acetone-treated skin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) 5% in ethanol applied in a chamber for 4 hours on mild dermatitis (1% SLS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) 5% in ethanol applied in a chamber for 4 hours on severe dermatitis (2% SLS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salicylic acid (SA) 5% in ethanol applied in a chamber for 4 hours on tape stripped skin
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Correlation of SA penetration with TEWL measurements
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Correlation of SA penetration with erythema measurements
Number of subjects: 18
Study: 7749166

Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron) 5 mg once daily
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron) 10 mg once daily
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Day 1, 0.2 mg/kg i.v.; Days 2-6, 8 mg p.o.)
Number of subjects: 1072

Group type: EXPERIMENTAL
Intervention: Alizapride (Day 1, 100 mg i.v. and 4 x 50 mg p.o.; Days 2-6, 4 x 5 mg p.o.)
Number of subjects: 1072

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study: 1968783

Group type: EXPERIMENTAL
Intervention: 100 mg esmolol IV
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 200 mg esmolol IV
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 6152977

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Mesterolone (M)
Number of subjects: 26
Study: 6139042

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium (0.1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 0
Study: 31340853

Group type: EXPERIMENTAL
Intervention: Standard printed patient information materials with access to a multimedia information resource
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard printed patient information materials alone
Number of subjects: 0
Study: 30131296

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 148

Group type: COMPARATOR
Intervention: Inhaled normal saline (placebo)
Number of subjects: 148
Study: 27827358

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs) treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 25450275

Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 396

Group type: COMPARATOR
Intervention: Traditional chemotherapy
Number of subjects: 396
Study: 22459648

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study: 20146631

Group type: EXPERIMENTAL
Intervention: elvitegravir 50 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: elvitegravir 125 mg
Number of subjects: 278

Group type: COMPARATOR
Intervention: CPI/r
Number of subjects: 278
Study: 17875063

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone 25/250 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 16158032

Group type: EXPERIMENTAL
Intervention: MIAS
Number of subjects: 72

Group type: COMPARATOR
Intervention: TPA
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: RPA
Number of subjects: 72
Study: 12074254

Group type: EXPERIMENTAL
Intervention: Olestra-substituted diet (31% metabolizable fat) for 14 days in Study One
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Olestra-containing diet (31% metabolizable fat) for 10 weeks in Study Two
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet (40% fat) for 10 weeks in Study Two
Number of subjects: 25

Group type: COMPARATOR
Intervention: Reduced-fat diet (31% fat) for 10 weeks in Study Two
Number of subjects: 25
Study: 10086544

Group type: EXPERIMENTAL
Intervention: Aprotinin therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8775646

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 2246794

Group type: EXPERIMENTAL
Intervention: Cognitive Marital Therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (programmed marital enhancement text)
Number of subjects: 33
Study: 7404146

Group type: EXPERIMENTAL
Intervention: Etomidate (Hypnomidate)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 80
Study: 31713631

Group type: EXPERIMENTAL
Intervention: DDD-CLS pacing algorithm for 12 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: DDI group (sham DDI mode)
Number of subjects: 54
Study: 29127575

Group type: EXPERIMENTAL
Intervention: Bright white light (BWL) therapy for 30 minutes daily for 28 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Dim red light (DRL) therapy for 30 minutes daily for 28 days
Number of subjects: 81
Study: 28485261

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 0
Study: 25442724

Group type: EXPERIMENTAL
Intervention: Gow-Gates technique
Number of subjects: 125

Group type: COMPARATOR
Intervention: Vazirani-Akinosi technique
Number of subjects: 125
Study: 23711998

Group type: EXPERIMENTAL
Intervention: Computer-based intervention (CBI)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Therapist-based intervention (TBI)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control
Number of subjects: 328
Study: 21332628

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus statin (EZE/statin)
Number of subjects: 21794

Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 21794
Study: 18362594

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.01-0.04 microg x kg x min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Melatonin (3.0 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 17174195

Group type: EXPERIMENTAL
Intervention: 8 mg NM-702
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: 4 mg NM-702
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: NM-702 (both doses)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 14702886

Group type: EXPERIMENTAL
Intervention: Postpartum mood disorder treatments (specific treatments not detailed in the abstract)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Screening instruments for postpartum mood disorders (specific instruments not detailed in the abstract)
Number of subjects: 1000
Study: 10879333

Group type: EXPERIMENTAL
Intervention: Substance abuse treatment with prenatal care
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (prenatal care only)
Number of subjects: 87
Study: 9487448

Group type: EXPERIMENTAL
Intervention: Regimen I (2EHRZ7/6EH7): 8-month daily regimen of ethambutol, isoniazid, rifampicin, and pyrazinamide for 2 months, followed by ethambutol and isoniazid for 6 months.
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Regimen II (2EHRZ2/4EHR2): 6-month twice-weekly regimen with the same four drugs for 2 months, followed by ethambutol, rifampicin, and isoniazid for 4 months.
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Regimen III (2HRZ2/4HR2): similar to Reg. II, but without ethambutol.
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Regimen I for isoniazid resistant group (94 patients).
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Regimen II for isoniazid resistant group (59 patients).
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Regimen III for isoniazid resistant group (74 patients).
Number of subjects: 1203
Study: 8238493

Group type: EXPERIMENTAL
Intervention: High insulin infusion (3,620 +/‐ 476 pM)
Number of subjects: 9
Study: 3552204

Group type: EXPERIMENTAL
Intervention: Oral administration of cyclophosphamide
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous administration of cyclophosphamide
Number of subjects: 7
Study: 30312165

Group type: EXPERIMENTAL
Intervention: Herbal decoction (180 mL of Cassia fistula L pod's pericarp and Myristica fragrans Houtt arils)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mefenamic acid (500 mg orally twice daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Herbal decoction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Mefenamic acid
Number of subjects: 64
Study: 28489253

Group type: EXPERIMENTAL
Intervention: Collagen plug procedure
Number of subjects: 94

Group type: COMPARATOR
Intervention: Mucosal advancement flap surgery
Number of subjects: 94
Study: 26123683

Group type: EXPERIMENTAL
Intervention: Endotoxin exposure for 130 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: β‐1,3‐d‐Glucan exposure for 130 minutes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Endotoxin exposure
Number of subjects: 50
Study: 23899667

Group type: EXPERIMENTAL
Intervention: FeS (ferrous sulfate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: C (controls)
Number of subjects: 20
Study: 20924292

Group type: EXPERIMENTAL
Intervention: 3-dimensional simulation training (1-hour session)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard training on pedicle screw insertion
Number of subjects: 37
Study: 18230228

Group type: EXPERIMENTAL
Intervention: Emotional disclosure (EMO)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Best possible self (BPS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control condition (CTL)
Number of subjects: 63
Study: 16644785

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 12871321

Group type: EXPERIMENTAL
Intervention: Hormone therapy (n = 357; opposed (n = 290) and unopposed (n = 67))
Number of subjects: 719

Group type: COMPARATOR
Intervention: No treatment (control group, n = 362)
Number of subjects: 719
Study: 10741256

Group type: EXPERIMENTAL
Intervention: Semax administered intransally as nasal drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semax administered by endonasal electrophoresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no semax)
Number of subjects: 0
Study: 8781668

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity to common airborne allergens
Number of subjects: 2841

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) reactivity
Number of subjects: 2841
Study: 1594787

Group type: EXPERIMENTAL
Intervention: Endotracheal tubes with 'rediffusion system'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Endotracheal tubes without 'rediffusion system'
Number of subjects: 0
Study: 6384851

Group type: EXPERIMENTAL
Intervention: Antifibrinolytic therapy (tranexamic acid)
Number of subjects: 360

Group type: COMPARATOR
Intervention: No antifibrinolytic therapy (Control)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Lateral cervical sutures
Number of subjects: 360
Study: 30981026

Group type: EXPERIMENTAL
Intervention: Dual use of e‐cigarettes and cigarettes (11.1% of cigarette users)
Number of subjects: 727

Group type: COMPARATOR
Intervention: Cigarette-only smokers
Number of subjects: 727
Study: 30537714

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 90
Study: 26980919

Group type: EXPERIMENTAL
Intervention: Flurbiprofen spray (3 times daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo solution (3 times daily)
Number of subjects: 84
Study: 24350736

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound localization (IUL)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional microsurgery
Number of subjects: 107
Study: 22902096

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bezafibrate (400 mg daily)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined treatment (Simvastatin and Bezafibrate)
Number of subjects: 14
Study: 19953579

Group type: EXPERIMENTAL
Intervention: 1.5 mg epinephrine plus normal saline (group 1; n = 38)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 1.5 mg epinephrine plus 3% saline (group 2; n = 39)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 2.5 mg salbutamol plus normal saline (group 3; n = 36)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 2.5 mg salbutamol plus 3% saline (group 4; n = 36)
Number of subjects: 186

Group type: COMPARATOR
Intervention: normal saline alone (group 5; n = 37)
Number of subjects: 186
Study: 17683650

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 220000

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 220000

Group type: EXPERIMENTAL
Intervention: Prophylactic bisphosphonate intervention
Number of subjects: 220000
Study: 15896289

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait list (control)
Number of subjects: 30
Study: 12585098

Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin principle (YQYY)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional method with corticosteroids and/or immunosuppressant
Number of subjects: 40
Study: 10029403

Group type: EXPERIMENTAL
Intervention: Education on infant behaviors, states, and communication cues
Number of subjects: 29
Study: 7564842

Group type: EXPERIMENTAL
Intervention: Pharyngeal constrictor myotomy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Unilateral pharyngeal plexus neurectomy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Unilateral pharyngeal plexus neurectomy with drainage myotomy limited to the cricopharyngeus
Number of subjects: 29
Study: 1300803

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and preoperative radiotherapy
Number of subjects: 387

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 387
Study: 3895037

Group type: EXPERIMENTAL
Intervention: Isoniazid therapy (up to 1200 mg/d)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31362667

Group type: EXPERIMENTAL
Intervention: VIP variants genotyping via Sequenom's MassARRAY® genotyping platform (iPLEX GOLD)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Comparison of allelic frequencies with 18 other populations
Number of subjects: 130
Study: 29610630

Group type: EXPERIMENTAL
Intervention: Cryoprobe biopsy (CB)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Flexible forceps biopsy (FFB)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Closed pleural biopsy (CPB)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Cytological cell block (CCB)
Number of subjects: 92
Study: 27038406

Group type: EXPERIMENTAL
Intervention: Braun anastomosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-Braun anastomosis
Number of subjects: 60
Study: 23512235

Group type: EXPERIMENTAL
Intervention: Intra-space injection of Twin mix
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Submucosal dexamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Per-oral dexamethasone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 60
Study: 21827450

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19858140

Group type: EXPERIMENTAL
Intervention: L-FMC after isometric exercise
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: FMD after isometric exercise
Number of subjects: 112

Group type: COMPARATOR
Intervention: Combination of L-FMC and FMD
Number of subjects: 112
Study: 17645472

Group type: EXPERIMENTAL
Intervention: peg‐IFN 1.0 mug/kg/week + ribavirin 10.6 mg/kg/day
Number of subjects: 103

Group type: COMPARATOR
Intervention: peg‐IFN 1.5 microg/kg/week + ribavirin 10.6 mg/kg/day
Number of subjects: 103
Study: 15980699

Group type: COMPARATOR
Intervention: VaxGen VAX004 study (HIV vaccine efficacy trial)
Number of subjects: 5417
Study: 12021683

Group type: EXPERIMENTAL
Intervention: Transitional Care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study: 9419453

Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P2 (group 5)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P1 (group 4)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Peptides alone (PSM-P1 or PSM-P2; group 1 and 2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Autologous DC (group 3)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: DC pulsed with PSM-P1 or PSM-P2 (group 4 and 5)
Number of subjects: 51
Study: 8089248

Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride (CPC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.1% cetylpyridinium chloride (CPC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Triclosan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control rinse (minus active)
Number of subjects: 20
Study: 2841251

Group type: EXPERIMENTAL
Intervention: Enalapril (20-40 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Captopril (50-100 mg)
Number of subjects: 69
Study: 31661606

Group type: EXPERIMENTAL
Intervention: Elevated serum CA19‐9 levels
Number of subjects: 27009

Group type: COMPARATOR
Intervention: Weighted genetic risk score for CA19‐9
Number of subjects: 27009
Study: 29016835

Group type: EXPERIMENTAL
Intervention: MVS with epicardial left atrial cryoablation
Number of subjects: 65

Group type: COMPARATOR
Intervention: MVS alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Patients with sinus rhythm
Number of subjects: 65

Group type: COMPARATOR
Intervention: Patients with AF
Number of subjects: 65
Study: 28494795

Group type: COMPARATOR
Intervention: Enhanced standard of care
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Experimental condition (enhanced standard of care + group-based intervention)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Both conditions (averaging over study condition)
Number of subjects: 128
Study: 26044206

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 36
Study: 23642946

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 21088546

Group type: EXPERIMENTAL
Intervention: Clay surface
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carpet surface
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Forehand stroke on clay
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Backhand stroke on clay
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Forehand stroke on carpet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Backhand stroke on carpet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Same stroke at different velocities
Number of subjects: 10
Study: 18311770

Group type: EXPERIMENTAL
Intervention: 1-year coaching program for healthy physical activity
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (standard care without additional coaching)
Number of subjects: 228
Study: 16284232

Group type: EXPERIMENTAL
Intervention: Eprosartan 600 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12744544

Group type: EXPERIMENTAL
Intervention: Breathing supplemental oxygen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breathing air
Number of subjects: 20
Study: 10902987

Group type: EXPERIMENTAL
Intervention: Energy supplement (1171 kJ + 12 mg iron)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Micronutrient supplement (209 kJ + 12 mg iron)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control (104 kJ)
Number of subjects: 136
Study: 9166392

Group type: EXPERIMENTAL
Intervention: HRT (2 mg estradiol valerate and 1 mg cyproterone acetate)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: HRT + Vit D (2 mg estradiol valerate and 1 mg cyproterone acetate + 300 IU/day vitamin D3)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Vit D (300 IU/day)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo (calcium lactate; 93 mg Ca2+/day)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: HRT + Vit D
Number of subjects: 464

Group type: COMPARATOR
Intervention: Vit D
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 8335785

Group type: EXPERIMENTAL
Intervention: Sealants applied with a bonding agent on wet enamel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sealants applied without a bonding agent on wet enamel
Number of subjects: 0
Study: 3541421

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN) given orally within the current therapeutic range
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN)
Number of subjects: 0
Study: 30246754

Group type: EXPERIMENTAL
Intervention: Fiber-reinforced composite (FRC) space maintainer (INFIBRA®: Reinforcing ribbon, Bioloren, Italy)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Band and loop space maintainers
Number of subjects: 50
Study: 26573925

Group type: EXPERIMENTAL
Intervention: liraglutide (0.6 mg for 2 days, 1.2 mg for 2 days, followed by 1.8 mg for 3 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 90

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90